Greenberg Jacques, Jayarajan Senthil, Reddy Sridhar, Schmieder Frank A, Roberts Andrew B, van Bemmelen Paul S, Lee Jean, Choi Eric T
1 Division of Vascular and Endovascular Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
2 Section of Vascular Surgery, Washington University School of Medicine, MO, USA.
Vasc Endovascular Surg. 2017 Apr;51(3):125-130. doi: 10.1177/1538574417692454. Epub 2017 Jan 1.
Dialysis access failure is a major cause of morbidity in patients with end-stage renal disease. The Fistula First Breakthrough Initiative (FFBI) dictates arteriovenous fistulae (AVFs) should be preferred over arteriovenous grafts (AVGs) as first line for surgically placed accesses. The purpose of this study was to compare patency rates of surgical dialysis accesses in our mature, urban population after the FFBI.
Current dialysis patients with accesses placed between 2006 and 2011 were included. Patient characteristics, access outcomes, interventions, and survival outcomes were analyzed.
We report outcomes of 220 patients undergoing dialysis access. Of those 220, 75 received numerous accesses. All outcomes are evaluated as per access itself, that is, a patient may have numerous access types, each individually analyzed. Of the accesses, 138 were AVF and 190 were AVG. The average age of patients was 59.8 years. The groups were evenly matched in distribution of race and prevalence of hypertension, diabetes, coronary artery disease, and Peripheral Vascular Disease (PVD). Average number of complications requiring intervention per access were fewer with AVF than AVG (1.21 vs 1.72, P = .02). The AVF had greater rates of stenosis (51.4% vs 40.6%, P = .0182), whereas AVG had greater thrombosis rates (14.6% vs 31.9%, P < .001). Both AVF and AVG had similar primary patency (median: 186 vs 142 days, P = .1774) and 3-year secondary patency (59.2% vs 49.2%, P = .0945). Arteriovenous fistula in patients aged <60 years was found to have the greatest primary ( P = .0078) and secondary patency ( P = .0400). Outcomes did not differ between AVF and AVG in those aged >60 years.
Although complications requiring intervention are greater with AVG, primary and secondary patency rates are similar between AVF and AVG, except when considering AVF in patients aged <60 years.
透析通路失败是终末期肾病患者发病的主要原因。“动静脉内瘘优先突破计划”(FFBI)规定,动静脉内瘘(AVF)应优先于动静脉移植物(AVG)作为手术建立通路的一线选择。本研究的目的是比较FFBI实施后我们成熟城市人群中手术透析通路的通畅率。
纳入2006年至2011年期间建立通路的现症透析患者。分析患者特征、通路结局、干预措施和生存结局。
我们报告了220例接受透析通路手术患者的结局。在这220例患者中,75例接受了多次通路手术。所有结局均根据每个通路本身进行评估,即一名患者可能有多种通路类型,每种类型单独分析。在这些通路中,138例为AVF,190例为AVG。患者的平均年龄为59.8岁。两组在种族分布以及高血压、糖尿病、冠状动脉疾病和外周血管疾病(PVD)患病率方面分布均衡。每例通路需要干预的并发症平均数量,AVF比AVG少(1.21对1.72,P = 0.02)。AVF的狭窄率更高(51.4%对40.6%,P = 0.0182),而AVG的血栓形成率更高(14.6%对31.9%,P < 0.001)。AVF和AVG的初始通畅率相似(中位数:186天对142天,P = 0.1774),3年的二次通畅率也相似(59.2%对49.2%,P = 0.0945)。发现年龄<60岁患者的动静脉内瘘初始通畅率(P = 0.0078)和二次通畅率最高(P = 0.0400)。年龄>60岁患者中,AVF和AVG的结局无差异。
虽然AVG需要干预的并发症更多,但AVF和AVG的初始通畅率和二次通畅率相似,年龄<60岁患者的动静脉内瘘情况除外。